Datu-oto, Caberan, JR.. .
HRN: 25-41-30 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/02/2024
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
07/02/2024
07/09/2024
IV
500mg
Q6
Cerebral Abscess
Waiting Final Action
Indication: Empiric Type of Infection: Central Nervous System Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes